US03969K1088
US03969K1088
Arcutis Biotherapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 3.34B EUR | 3.29B EUR | 2.95B EUR | 3.58B EUR |
Enterprise Value | 2.95B EUR | 3.37B EUR | 3.03B EUR | 3.65B EUR |
Valuation Multiples | ||||
Trailing P/E | 120.82x | 115.47x | -- | 401.57x |
Forward P/E | 19.54x | -- | -- | -- |
Price to Sales | 7.2x | 7.1x | 7.09x | 11.55x |
Price to Book | 15.14x | 14.93x | 15.53x | 18.9x |
EV/Revenue | 6.37x | 7.27x | 7.28x | 11.77x |
EV/EBITDA | 80.92x | 74.31x | 211.19x | 177.33x |
Price to FCF (P/FCF) | 154.06x | 84.11x | 174.15x | 244.03x |
EV/FCF | 136.21x | 86.15x | 178.88x | 248.89x |
FCF Yield | 0.65% | 1.19% | 0.57% | 0.41% |